Back to Search Start Over

Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus.

Authors :
Lucci, Claudia
Cosentino, Nicola
Genovese, Stefano
Campodonico, Jeness
Milazzo, Valentina
De Metrio, Monica
Rondinelli, Maurizio
Riggio, Daniela
Biondi, Maria Luisa
Rubino, Mara
Celentano, Katia
Bonomi, Alice
Capra, Nicolò
Veglia, Fabrizio
Agostoni, Piergiuseppe
Bartorelli, Antonio L.
Marenzi, Giancarlo
Source :
Cardiovascular Diabetology; 10/20/2020, Vol. 19 Issue 1, p1-13, 13p
Publication Year :
2020

Abstract

Background: High-sensitivity C-reactive protein (hs-CRP) elevation frequently occurs in acute myocardial infarction (AMI) and is associated with adverse outcomes. Since diabetes mellitus (DM) is characterized by an underlying chronic inflammation, hs-CRP may have a different prognostic power in AMI patients with and without DM. Methods: We prospectively included 2064 AMI patients; hs-CRP was measured at hospital admission. Patients were grouped according to hs-CRP quartiles and DM status. The primary endpoint was a composite of in-hospital mortality, cardiogenic shock, and acute pulmonary edema. Two-year all-cause mortality was the secondary endpoint. Results: Twenty-six percent (n = 548) of patients had DM and they had higher hs-CRP levels than non-DM patients (5.32 vs. 3.24 mg/L; P < 0.0001). The primary endpoint incidence in the overall population (7%, 9%, 13%, 22%; P for trend < 0.0001), in DM (14%, 9%, 21%, 27%; P = 0.0001), and non-DM (5%, 8%, 10%, 19%; P < 0.0001) patients increased in parallel with hs-CRP quartiles. The adjusted risk of the primary endpoint increased in parallel with hs-CRP quartiles in DM and non-DM patients but this relationship was less evident in DM patients. In the overall population, the adjusted OR of the primary endpoint associated with an hs-CRP value ≥ 2 mg/L was 2.10 (95% CI 1.46-3.00). For the same risk, hs-CRP was 7 and 2 mg/L in patients with and without DM. A similar behavior was observed for the secondary endpoint when the HR associated with an hs-CRP value ≥ 2 mg/L found in the overall population was 2.25 (95% CI 1.57-3.22). For the same risk, hs-CRP was 8 and 1.5 mg/L in DM and non-DM patients. Conclusions: This study shows that hs-CRP predicts in-hospital outcome and two-year mortality in AMI patients with and without DM. However, in DM patients, the same risk of developing events as in non-DM patients is associated to higher hs-CRP levels. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14752840
Volume :
19
Issue :
1
Database :
Complementary Index
Journal :
Cardiovascular Diabetology
Publication Type :
Academic Journal
Accession number :
146530369
Full Text :
https://doi.org/10.1186/s12933-020-01157-7